Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2022-04-19 Regulatory Filings
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(신규 항체-약물 결합체(ADC) 연구개발을 위한 항체 기술도입 계약 체결)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (LegoChem Biosciences) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a specific technology licensing agreement for ADC research and development. Since this is a formal regulatory disclosure of a material business event (a contract signing) rather than a financial report, a transcript, or a simple announcement of a report, it falls under the 'Regulatory Filings' category as the most appropriate fallback for miscellaneous material corporate disclosures.
2022-04-19 Korean
주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions. This type of corporate action regarding share-based compensation and capital changes is best classified under 'Share Issue/Capital Change' (SHA) as it relates to the potential issuance of new shares or treasury shares to employees.
2022-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과) for LegoChem Biosciences. It details the outcomes of various agenda items, including the approval of financial statements, election of directors and auditors, and other resolutions. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-03-31 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange by LegoChem Biosciences. It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions. Since this document pertains to the issuance of new shares or capital-related instruments (stock options) and does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it is best classified as a Regulatory Filing (RNS) as it is a mandatory disclosure of a corporate action.
2022-03-31 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/proper), key financial data, and auditor information for the fiscal year. While it contains financial data, it is a summary disclosure of the audit results rather than the full annual report (10-K) or a standalone audit report (AR). In the context of Korean regulatory filings, this specific disclosure format is categorized as a report publication announcement or regulatory filing regarding the audit status. FY 2021
2022-03-23 Korean
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for LegoChem Biosciences for the fiscal year 2021. It contains comprehensive company information, financial data, capital structure, and governance details, which is the standard format for an Annual Report (10-K equivalent in the Korean market). FY 2021
2022-03-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.